導出完成 — 
載入...

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

Seventy-five percent of lung adenocarcinomas with epidermal growth factor receptor (EGFR) mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib; however, drug-resistant tumors eventually emerge. In 60% of cases, resistant tumors carry a secondary mutation...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Politi, Katerina, Fan, Pang-Dian, Shen, Ronglai, Zakowski, Maureen, Varmus, Harold
格式: Artigo
語言:Inglês
出版: The Company of Biologists Limited 2010
主題:
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC2806903/
https://ncbi.nlm.nih.gov/pubmed/20007486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1242/dmm.003681
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!